NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research (U24 Clinical Trial Not Allowed) | PAR 22 110

Opportunity Information: Apply for PAR 22 110

The National Institute on Aging (NIA), part of the National Institutes of Health (NIH), is offering a discretionary funding opportunity called "NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research (U24 Clinical Trial Not Allowed)" (PAR 22-110). This announcement is specifically designed for organizations that already hold an active, funded U24 research resource or infrastructure award in the Alzheimer s disease (AD) and Alzheimer s disease-related dementias (ADRD) space and now want to either renew that support or request a competitive revision to expand or modify the scope of the existing program. Resubmissions of renewal and competitive revision applications are also allowed under this FOA, meaning applicants can revise and reapply if an earlier attempt was not funded. The intent is to sustain and strengthen large-scale, complex AD/ADRD research programs that function as shared resources or infrastructure, rather than stand-alone, single-investigator research projects.

A key theme of the opportunity is scale and coordination. NIA expects supported efforts to be big enough to require a team-based approach, either within one institution or through a multi-institution consortium. These U24s are meant to enable the broader AD/ADRD research community by providing resources, platforms, coordinating centers, data systems, networks, or other infrastructure that multiple investigators and projects can rely on. Importantly, these activities are expected to align with one or more AD/ADRD implementation research milestones that support the federal research priorities laid out in the National Plan to Address Alzheimer s and Related Dementias. In other words, the program is not just about maintaining a resource; it is about keeping that resource clearly connected to national AD/ADRD goals and measurable progress points.

The award mechanism is a Cooperative Agreement (U24), which generally implies substantial involvement from NIH program staff compared with a standard research grant. While applicants still propose and lead the work, the cooperative agreement structure typically includes active collaboration with NIA on governance, milestones, coordination, and programmatic direction. The FOA is also explicit that clinical trials are not allowed under this specific announcement. That restriction matters for applicants planning human subjects activities: the project can support infrastructure, coordination, data resources, and related functions, but it cannot include a clinical trial as defined by NIH.

Eligibility is broad across many U.S.-based organization types, reflecting the infrastructure nature of U24 programs. Eligible applicants include various levels of government (state, county, city/township, special districts), independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized Native American tribal governments, tribal organizations that are not federally recognized, public housing authorities/Indian housing authorities, nonprofits with or without 501(c)(3) status (other than institutions of higher education), for-profit organizations other than small businesses, and small businesses. The FOA also highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions. This wide range is intended to encourage strong, sustainable infrastructure programs wherever the appropriate expertise and capacity exist.

Foreign participation is addressed with some nuance. Non-domestic (non-U.S.) entities or foreign institutions are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are also not eligible to apply. However, "foreign components" as defined in the NIH Grants Policy Statement are allowed, meaning a U.S. applicant may include certain foreign collaborations or elements when they meet NIH policy definitions and are justified as part of the overall program. This distinction is important for AD/ADRD research resources that may benefit from international expertise, datasets, or coordination, while still keeping the prime award and leadership within an eligible U.S. organization.

From the administrative details provided, the CFDA number listed is 93.866, the opportunity was created on February 3, 2022, and the original closing date is September 25, 2024. The FOA does not list an award ceiling or expected number of awards in the provided text, which usually means applicants need to consult the full FOA or related NIA guidance for budget expectations, project period norms, and programmatic fit.

In practical terms, this opportunity is best understood as a way for existing NIA-funded AD/ADRD U24 resource and infrastructure programs to continue operating, modernize, scale, or adjust to emerging scientific and implementation needs without having to start from scratch under a brand-new mechanism. Competitive revisions can be especially relevant when a resource needs to add new functionality, serve a larger community, integrate new data types, improve interoperability, or respond to evolving national milestones, while renewals focus on continued support and demonstrated value of the established infrastructure. The overall goal is to keep critical AD/ADRD research resources strong, coordinated, and directly tied to the national strategy for addressing Alzheimer s and related dementias.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research (U24 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
• This funding opportunity was created on 2022-02-03.
• Applicants must submit their applications by 2024-09-25. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 22 110

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: